Targeting platelet GPIbβ reduces platelet adhesion, gpib signaling and thrombin generation and prevents arterial thrombosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 6, 2013, Pages 1221-1229

  Maurer, Eric ^a   Tang, Chaojun ^a   Schaff, Mathieu ^a   Bourdon, Catherine ^a   Receveur, Nicolas ^a   Ravanat, Catherine ^a   Eckly, Anita ^a   Hechler, Béatrice ^a   Gachet, Christian ^a   Lanza, Francois ^a   Mangin, Pierre H ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Hemostasis; Platelets; Thrombosis; Von Willebrand factor

Indexed keywords

ANTITHROMBOCYTIC AGENT; CALCIUM; GLYCOPROTEIN IB; GLYCOPROTEIN IB BETA; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY; PHOSPHATIDYLSERINE; RAM 1 MONOCLONAL ANTIBODY; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LASER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION;

HEMOSTASIS; PLATELETS; THROMBOSIS; VON WILLEBRAND FACTOR;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BLEEDING TIME; CELL ADHESION; CRICETINAE; DISEASE MODELS, ANIMAL; HUMANS; MICE; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; RANDOM ALLOCATION; RATS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE III; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84879097179     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.301013     Document Type: Article

References (41)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
2. Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84:289-297.
3. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest. 2000;105:783-791.
4. Dörmann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood. 2000;96:2469-2478.
5. Béguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood. 1999;93:564-570.
6. Béguin S, Keularts I, Al Dieri R, Bellucci S, Caen J, Hemker HC. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. J Thromb Haemost. 2004;2:170-176.
7. Ravanat C, Strassel C, Hechler B, Schuhler S, Chicanne G, Payrastre B, Gachet C, Lanza F. A central role of GPIb-IX in the procoagulant function of platelets that is independent of the 45-kDa GPIbalpha N-terminal extracellular domain. Blood. 2010;116:1157-1164.
8. Cauwenberghs N, Meiring M, Vauterin S, van Wyk V, Lamprecht S, Roodt JP, Novák L, Harsfalvi J, Deckmyn H, Kotzé HF. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol. 2000;20:1347-1353.
9. Diener JL, Daniel Lagassé HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R, Gilbert J, Wagner DD, Schaub R. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the antivon Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost. 2009;7:1155-1162.
10. Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, Priem S, Lauwereys M, Casteels P, Van Bockstaele F, Verschueren K, Stanssens P, Baumeister J, Holz JB. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118:757-765.
11. Chang MC, Lin HK, Peng HC, Huang TF. Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox. Blood. 1998;91:1582-1589.
12. Konstantinides S, Ware J, Marchese P, Almus-Jacobs F, Loskutoff DJ, Ruggeri ZM. Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis. J Thromb Haemost. 2006;4:2014-2021.
13. Bergmeier W, Piffath CL, Goerge T, Cifuni SM, Ruggeri ZM, Ware J, Wagner DD. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A. 2006;103:16900-16905.
14. Azzam K, Garfinkel LI, Bal dit Sollier C, Cisse Thiam M, Drouet L. Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries. Thromb Haemost. 1995;73:318-323.
15. Bonnefoy A, Vermylen J, Hoylaerts MF. Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev Cardiovasc Ther. 2003;1:257-269.
16. Vanhoorelbeke K, Ulrichts H, Van de Walle G, Fontayne A, Deckmyn H. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr Pharm Des. 2007;13:2684-2697.
17. Clemetson KJ, Clemetson JM. Platelet GPIb complex as a target for antithrombotic drug development. Thromb Haemost. 2008;99:473-479.
18. Mo X, Lu N, Padilla A, López JA, Li R. The transmembrane domain of glycoprotein Ibbeta is critical to efficient expression of glycoprotein Ib-IX complex in the plasma membrane. J Biol Chem. 2006;281:23050-23059.
19. Mo X, Liu L, López JA, Li R. Transmembrane domains are critical to the interaction between platelet glycoprotein V and glycoprotein Ib-IX complex. J Thromb Haemost. 2012;10:1875-1886.
20. Luo SZ, Mo X, Afshar-Kharghan V, Srinivasan S, López JA, Li R. Glycoprotein Ibalpha forms disulfide bonds with 2 glycoprotein Ibbeta subunits in the resting platelet. Blood. 2007;109:603-609.
21. Williamson D, Pikovski I, Cranmer SL, Mangin P, Mistry N, Domagala T, Chehab S, Lanza F, Salem HH, Jackson SP. Interaction between platelet glycoprotein Ibalpha and filamin-1 is essential for glycoprotein Ib/IX receptor anchorage at high shear. J Biol Chem. 2002;277:2151-2159.
22. Cranmer SL, Ashworth KJ, Yao Y, Berndt MC, Ruggeri ZM, Andrews RK, Jackson SP. High shear-dependent loss of membrane integrity and defective platelet adhesion following disruption of the GPIbα-filamin interaction. Blood. 2011;117:2718-2727.
23. Kanaji T, Ware J, Okamura T, Newman PJ. GPIbα regulates platelet size by controlling the subcellular localization of filamin. Blood. 2012;119:2906-2913.
24. Jurak Begonja A, Hoffmeister KM, Hartwig JH, Falet H. FlnA-null megakaryocytes prematurely release large and fragile platelets that circulate poorly. Blood. 2011;118:2285-2295.
25. Gu M, Xi X, Englund GD, Berndt MC, Du X. Analysis of the roles of 14-3-3 in the platelet glycoprotein Ib-IX-mediated activation of integrin alpha(IIb)beta(3) using a reconstituted mammalian cell expression model. J Cell Biol. 1999;147:1085-1096.
26. Mangin P, David T, Lavaud V, Cranmer SL, Pikovski I, Jackson SP, Berndt MC, Cazenave JP, Gachet C, Lanza F. Identification of a novel 14-3-3zeta binding site within the cytoplasmic tail of platelet glycoprotein Ibalpha. Blood. 2004;104:420-427.
27. Mangin PH, Receveur N, Wurtz V, David T, Gachet C, Lanza F. Identification of five novel 14-3-3 isoforms interacting with the GPIb-IX complex in platelets. J Thromb Haemost. 2009;7:1550-1555.
28. Mangin P, Yuan Y, Goncalves I, Eckly A, Freund M, Cazenave JP, Gachet C, Jackson SP, Lanza F. Signaling role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization. Involvement of a pathway distinct from FcR gamma chain and Fc gamma RIIA. J Biol Chem. 2003;278:32880-32891.
29. David T, Strassel C, Eckly A, Cazenave JP, Gachet C, Lanza F. The platelet glycoprotein GPIbbeta intracellular domain participates in von Willebrand factor induced-filopodia formation independently of the Ser 166 phosphorylation site. J Thromb Haemost. 2010;8:1077-1087.
30. Perrault C, Moog S, Rubinstein E, Santer M, Baas MJ, de la Salle C, Ravanat C, Dambach J, Freund M, Santoso S, Cazenave JP, Lanza F. A novel monoclonal antibody against the extracellular domain of GPIbbeta modulates vWF mediated platelet adhesion. Thromb Haemost. 2001;86:1238-1248.
31. Perrault C, Mangin P, Santer M, Baas MJ, Moog S, Cranmer SL, Pikovski I, Williamson D, Jackson SP, Cazenave JP, Lanza F. Role of the intracellular domains of GPIb in controlling the adhesive properties of the platelet GPIb/V/IX complex. Blood. 2003;101:3477-3484.
32. Yan R, Mo X, Paredes AM, Dai K, Lanza F, Cruz MA, Li R. Reconstitution of the platelet glycoprotein Ib-IX complex in phospholipid bilayer Nanodiscs. Biochemistry. 2011;50:10598-10606.
33. Caen J, Bellucci S. The defective prothrombin consumption in Bernard-Soulier syndrome. Hypotheses from 1948 to 1982. Blood Cells. 1983;9:389-399.
34. Hechler B, Nonne C, Eckly A, Magnenat S, Rinckel JY, Denis CV, Freund M, Cazenave JP, Lanza F, Gachet C. Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost. 2010;8:173-184.
35. Mangin PH, Tang C, Bourdon C, Loyau S, Freund M, Hechler B, Gachet C, Jandrot-Perrus M. A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents. J Pharmacol Exp Ther. 2012;341:156-163.
36. Zhang W, Zhao L, Liu J, Du J, Yan R, Dai K. Role of 14-3-3ζ in platelet glycoprotein Ibα-von Willebrand factor interaction-induced signaling. Int J Mol Sci. 2012;13:5364-5374.
37. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998;94:657-666.
38. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
39. Lanza F. Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis. 2006;1:46.
40. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG. Firstin-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116:2678-2686.
41. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke. 2011;42:2149-2153. Médecine et Santé Publique